Managing Post-Peel PIH in Indian Skin: A Clinical Checklist

Post-inflammatory hyperpigmentation (PIH) is the complication that determines whether a chemical peel practice grows or stalls in India. The underlying maths is simple: a Fitzpatrick V patient who develops persistent PIH after what should have been a routine glycolic peel tells five people about their experience before the pigmentation resolves. Every unnecessary case of PIH costs the clinic roughly five potential patients.

This is not an argument against peels in darker skin — it is an argument for peels performed with the specific clinical discipline that Fitzpatrick IV–VI skin requires. This checklist walks through the pre-peel, peel-day, and post-peel protocol components that reduce PIH incidence to below the threshold where it becomes a practice-limiting problem.

Understanding Why PIH Happens

PIH is the post-injury inflammatory cascade's normal pigmentary consequence. When the skin is injured, prostaglandins, leukotrienes, and other inflammatory mediators stimulate melanocytes to produce excess melanin. In Fitzpatrick IV–VI skin, the baseline melanocyte responsiveness is higher, and the threshold for this pigmentary response is lower.

The critical insight for peel protocols is that the inflammatory cascade, not the injury itself, produces the pigmentation. This means the goal of a Fitzpatrick V peel protocol is not to minimise the peel — it is to minimise the inflammation per unit of peel effect. This distinction matters because it changes the intervention from "use weaker peels" to "use peels that produce a favourable inflammation-to-exfoliation ratio, and suppress the inflammation that does occur."

Pre-Peel: The 2-Week Window That Determines Outcomes

Most preventable PIH cases are preventable in the pre-peel window, not on peel day. The non-negotiable pre-peel protocol for Fitzpatrick V–VI:

Two weeks before the peel

Topical retinoid nightly (tretinoin 0.025%, tazarotene 0.05%, or adapalene 0.1% for retinoid-naive patients). This accomplishes epidermal thinning that makes peel penetration more uniform, reducing hot-spot frost and the associated inflammatory focal points.

Tyrosinase-inhibiting topical twice daily. Hydroquinone 4% is traditional; kojic acid 2–3% with azelaic acid 10% is equally effective with a substantially better long-term safety profile. The goal is to pacify melanocytes before the injury event, so they respond to the peel inflammation from a lower baseline activation state.

Daily SPF 50+ with iron oxide content. Standard chemical sunscreens that block only UV are insufficient for PIH prevention. Iron oxides in visible-light-blocking mineral sunscreens reduce post-peel melanogenesis measurably.

The 48-hour cutoff

Discontinue the retinoid 48 hours before the peel. Continuing retinoid to peel day increases the depth of peel injury unpredictably and the inflammatory response disproportionately. Continue the tyrosinase inhibitor and sunscreen up to peel day.

Peel Day: Protocol Modifications for Darker Skin

Degrease thoroughly but not aggressively

Incomplete degreasing produces uneven peel penetration — which produces uneven inflammation — which produces splotchy PIH. Aggressive degreasing with harsh solvents produces its own inflammatory insult.

Use acetone on gauze for 30 seconds per facial zone. Do not scrub. Visually confirm matte, oil-free surface before acid application.

Acid selection

Default to acids with favourable inflammation profiles:

• Mandelic acid — slowest penetration, lowest inflammatory profile
• Lactic acid — excellent hydration retention during exfoliation
• Salicylic acid — intrinsic anti-inflammatory effect from aspirin-like structure

Avoid high-concentration glycolic (above 30%) and avoid TCA at any concentration above 15% in Fitzpatrick VI without specific indication and experienced supervision.

Application technique

Apply in timed passes with cotton applicator. Count 60 seconds between each coat. Stop at the earliest visible endpoint — light frost in one zone means the peel is active, not that you need a second coat across the remaining areas.

Use a cool water compress at endpoint even if the acid is "self-neutralising." The compress reduces patient pain perception, which reduces patient anxiety, which reduces sympathetic inflammatory response. This is not just comfort theatre — it measurably reduces the immediate inflammatory cascade.

Immediate post-peel

Apply a ceramide-based barrier moisturiser to the entire treated area. Do not skip this because the skin "looks fine" — the ceramide deposition during the first hour post-peel measurably reduces trans-epidermal water loss and the associated inflammatory signalling.

Post-Peel: The First 14 Days

Days 1–3: Active barrier support

Patient applies ceramide moisturiser 3–4 times daily. No active ingredients — no retinoid, no AHA/BHA, no vitamin C. The skin is actively healing and adding actives during this window increases inflammation, not results.

Explicit patient instruction: no picking, no scrubbing, no hot showers on the treated area, sunscreen every 2 hours during daylight.

Days 4–7: Controlled desquamation

Expect visible peeling. Patient continues barrier support. Introduce a gentle mineral sunscreen with zinc + iron oxide if not already in use.

Tyrosinase-inhibiting topical resumes at day 5 at half the pre-peel frequency. This is the window where proactive melanocyte suppression has the highest return on investment.

Days 8–14: Active PIH suppression

If the peel was performed correctly, visible PIH should not be appearing. However, the melanocyte activation window extends to day 14, so continue active suppression:

• Resume full tyrosinase inhibitor frequency
• Introduce a tranexamic acid serum if available
• Continue daily SPF 50+ with iron oxide

Tranexamic acid has become the most useful addition to standard PIH prevention protocols. It inhibits plasminogen activation in keratinocytes, which reduces the melanogenic signalling that continues beyond the acute injury window.

When PIH Does Occur: The Graded Response

Despite optimal protocols, some PIH will occur. The response should be graded to severity:

Grade 1: Mild, patchy hyperpigmentation at 2–3 weeks

Response: aggressive tyrosinase inhibition + tranexamic acid + strict sun avoidance. Do not attempt to peel through it.

Expected resolution: 6–12 weeks with compliance.

Grade 2: Confluent hyperpigmentation affecting multiple facial zones

Response: formal PIH protocol with clinic-delivered depigmentation treatments, topical tranexamic acid, and oral tranexamic acid if no contraindications (250mg twice daily for 6–12 weeks under monitoring).

Expected resolution: 3–6 months.

Grade 3: Deep, stubborn pigmentation unresponsive at 3 months

Response: escalate to specialist referral. This is typically not residual PIH — it is activation of previously-quiescent melasma, which requires its own long-term management strategy.

The Systemic Considerations Most Clinics Miss

Iron status

Iron deficiency correlates with increased PIH risk and slower resolution. For patients presenting with PIH complaints or history of persistent PIH, check ferritin. Iron supplementation in deficient patients measurably improves PIH resolution rates.

Thyroid status

Subclinical hypothyroidism affects melanocyte activation thresholds. Any patient with persistent or disproportionate PIH who has not had recent thyroid testing should have TSH and free T4 checked before escalating peel protocols.

Sleep and cortisol

Sleep-deprived patients have elevated cortisol, which influences melanogenesis indirectly. This is rarely the primary cause but is worth acknowledging during the patient consultation, particularly for patients with refractory PIH who have been through multiple protocol revisions.

Patient Communication: The Neglected Intervention

A significant portion of "PIH complications" are actually patient perception problems. A patient who expected to look camera-ready on day 3 sees the normal desquamation as a problem. A patient who expected a 3-day recovery is angry at day 7.

Standard pre-peel consultation components that prevent perception problems:

1. Show photographs of normal day-3 and day-7 post-peel appearance. Visual anchoring prevents the "this is worse than I thought" reaction.
2. Explicitly state the PIH risk as a percentage. "About 10% of patients with your skin type develop some temporary darkening that takes 2–3 months to clear" is a factual frame that lets the patient consent with eyes open.
3. Schedule the 2-week post-peel visit before the peel is performed. The follow-up being on the calendar changes how the patient processes the intervening week.

The Protocol Audit Question

If your clinic is running more than 15% PIH rate in Fitzpatrick V–VI peels, the protocol has a specific failure point that can usually be identified by auditing three variables:

1. Priming compliance. Are patients actually using the pre-peel regimen for 2 weeks, or are they starting 3 days before?
2. Acid selection by Fitzpatrick type. Are high-concentration glycolic peels being used as defaults in Fitzpatrick V?
3. Post-peel sunscreen compliance. Are patients using adequate SPF 50+ with iron oxide, or are they relying on inadequate alternatives?

Fixing the highest-yield variable typically drops PIH rates by half within 8 weeks of audit. The protocol change is free; the reputation upside is substantial.

Key Takeaways

1. PIH is a preventable complication, not an acceptable cost of doing business. Clinics that treat it as inevitable undertreat the prevention protocol.
2. The 2-week pre-peel window determines more outcomes than the peel day itself. Priming compliance is the single highest-leverage variable.
3. Inflammation drives pigmentation. Select acids by their inflammation-to-exfoliation ratio, not by concentration or familiarity.
4. Post-peel sunscreen must include iron oxide in darker skin. Standard UV-only sunscreens are insufficient for melanogenesis suppression.
5. Audit your own PIH rates quarterly. Without numerical feedback, practice drift produces complications that individual case memory will systematically under-count.